The DNA damage response and cancer therapy (original) (raw)

• Boveri, T. Zur Frage der Entstehung Maligner Tumoren (Gustav Fischer, 1914).
  Google Scholar
• Boveri, T. Concerning the origin of malignant tumours by Theodor Boveri. Translated and annotated by Henry Harris. J. Cell Sci. 121, 1–84 (2008). A translation of Boveri's original work that proposed the hypothesis that a form of genomic dysregulation characterizes tumour cells.
  Article PubMed Google Scholar
• Ciccia, A. & Elledge, S. J. The DNA damage response: making it safe to play with knives. Mol. Cell 40, 179–204 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Hoeijmakers, J. H. DNA damage, aging, and cancer. N. Engl. J. Med. 361, 1475–1485 (2009).
  Article CAS PubMed Google Scholar
• Phillips, D. H., Hewer, A., Martin, C. N., Garner, R. C. & King, M. M. Correlation of DNA adduct levels in human lung with cigarette smoking. Nature 336, 790–792 (1988).
  Article ADS CAS PubMed Google Scholar
• David, S. S., O'Shea, V. L. & Kundu, S. Base-excision repair of oxidative DNA damage. Nature 447, 941–950 (2007).
  Article ADS CAS PubMed PubMed Central Google Scholar
• Nakabeppu, Y. et al. Mutagenesis and carcinogenesis caused by the oxidation of nucleic acids. Biol. Chem. 387, 373–379 (2006).
  Article CAS PubMed Google Scholar
• Cleaver, J. E., Lam, E. T. & Revet, I. Disorders of nucleotide excision repair: the genetic and molecular basis of heterogeneity. Nature Rev. Genet. 10, 756–768 (2009).
  Article CAS PubMed Google Scholar
• Moynahan, M. E. & Jasin, M. Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nature Rev. Mol. Cell Biol. 11, 196–207 (2010).
  Article CAS Google Scholar
• Lieber, M. R. NHEJ and its backup pathways in chromosomal translocations. Nature Struct. Mol. Biol. 17, 393–395 (2010).
  Article CAS Google Scholar
• Jiricny, J. The multifaceted mismatch-repair system. Nature Rev. Mol. Cell Biol 7, 335–346 (2006).
  Article CAS Google Scholar
• Artandi, S. E. & DePinho, R. A. Telomeres and telomerase in cancer. Carcinogenesis 31, 9–18 (2010).
  Article CAS PubMed Google Scholar
• Stephens, P. J. et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144, 27–40 (2011).
  Article MathSciNet CAS PubMed PubMed Central Google Scholar
• Bell, O., Tiwari, V. K., Thoma, N. H. & Schubeler, D. Determinants and dynamics of genome accessibility. Nature Rev. Genet. 12, 554–564 (2011).
  Article CAS PubMed Google Scholar
• Warmerdam, D. O. & Kanaar, R. Dealing with DNA damage: relationships between checkpoint and repair pathways. Mutat. Res. 704, 2–11 (2010).
  Article CAS PubMed Google Scholar
• Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
  Article CAS PubMed Google Scholar
• Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609–615 (2011).
• Bartkova, J. et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444, 633–637 (2006).
  Article ADS CAS PubMed Google Scholar
• Halazonetis, T. D., Gorgoulis, V. G. & Bartek, J. An oncogene-induced DNA damage model for cancer development. Science 319, 1352–1355 (2008). References 18 and 19 describes how oncogenes are able to induce the DDR early in oncogenesis.
  Article ADS CAS PubMed Google Scholar
• Turner, N., Tutt, A. & Ashworth, A. Hallmarks of 'BRCAness' in sporadic cancers. Nature Rev. Cancer 4, 814–819 (2004).
  Article CAS Google Scholar
• Banerjee, S., Kaye, S. B. & Ashworth, A. Making the best of PARP inhibitors inovarian cancer. Nature Rev. Clin. Oncol. 7, 508–519 (2010).
  Article CAS Google Scholar
• Friboulet, L. et al. Molecular characteristics of ERCC1-negative versus ERCC1-positive tumors in resected NSCLC. Clin. Cancer Res. 17, 5562–5572 (2011).
  Article CAS PubMed Google Scholar
• Weller, M. et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nature Rev. Neurol. 6, 39–51 (2010).
  Article CAS Google Scholar
• Pommier, Y., Leo, E., Zhang, H. & Marchand, C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem. Biol. 17, 421–433 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H. & Poirier, G. G. PARP inhibition: PARP1 and beyond. Nature Rev. Cancer 10, 293–301 (2010).
  Article CAS Google Scholar
• Zaremba, T. & Curtin, N. J. PARP inhibitor development for systemic cancer targeting. Anticancer Agents Med. Chem. 7, 515–523 (2007).
  Article CAS PubMed Google Scholar
• Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917–921 (2005).
  Article ADS CAS PubMed Google Scholar
• Bryant, H. E. et al. Specific killing of _BRCA2_-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913–917 (2005). References 27 and 28 describe the synthetic lethal interaction between BRCA mutations and PARP inhibition.
  Article ADS CAS PubMed Google Scholar
• Lord, C. J. & Ashworth, A. Targeted therapy for cancer using PARP inhibitors. Curr. Opin. Pharmacol. 8, 363–369 (2008).
  Article CAS PubMed Google Scholar
• Dobzhansky, T. Genetics of natural populations. Xiii. Recombination and variability in populations of drosophila pseudoobscura . Genetics 31, 269–290 (1946).
  CAS PubMed PubMed Central Google Scholar
• Lucchesi, J. C. Synthetic lethality and semi-lethality among functionally related mutants of Drosophila melanogaster . Genetics 59, 37–44 (1968).
  CAS PubMed PubMed Central Google Scholar
• Hartwell, L. H., Szankasi, P., Roberts, C. J., Murray, A. W. & Friend, S. H. Integrating genetic approaches into the discovery of anticancer drugs. Science 278, 1064–1068 (1997).
  Article ADS CAS PubMed Google Scholar
• Kaelin, W. G. Jr. Synthetic lethality: a framework for the development of wiser cancer therapeutics. Genome Med. 1, 99 (2009).
  Article PubMed PubMed Central Google Scholar
• Issaeva, N. et al. 6-Thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance. Cancer Res. 70, 6268–6276 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Martin, S. A. et al. DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1. Cancer Cell 17, 235–248 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Martin, S. A., Hewish, M., Sims, D., Lord, C. J. & Ashworth, A. Parallel high-throughput RNA interference screens identify PINK1 as a potential therapeutic target for the treatment of DNA mismatch repair-deficient cancers. Cancer Res. 71, 1836–1848 (2011).
  Article CAS PubMed Google Scholar
• Martin, S. A. et al. Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2 . EMBO Mol. Med. 1, 323–337 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Fong, P. C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123–134 (2009). This article describes the results of the first clinical trial to demonstrate the clinical potential of a synthetic lethal approach for therapy.
  Article CAS PubMed Google Scholar
• Balmaña, J., Domchek, S. M., Tutt, A. & Garber, J. E. Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancers. Cancer Discov. 1, 29–34 (2011).
  Article PubMed Google Scholar
• Mendeleyev, J., Kirsten, E., Hakam, A., Buki, K. G. & Kun, E. Potential chemotherapeutic activity of 4-iodo-3-nitrobenzamide. Metabolic reduction to the 3-nitroso derivative and induction of cell death in tumor cells in culture. Biochem. Pharmacol. 50, 705–714 (1995).
  Article CAS PubMed Google Scholar
• Liu, X. et al. Iniparib non-selectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clin. Cancer Res. advance ahead of print http://dx.doi.org/10.1158/1078-0432.CCR-11-1973 (29 November 2011).
• McCabe, N. et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 66, 8109–8115 (2006).
  Article CAS PubMed Google Scholar
• Peasland, A. et al. Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines. Br. J. Cancer 105, 372–381 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Murai, J. et al. The USP1/UAF1 complex promotes double-strand break repair through homologous recombination. Mol. Cell. Biol. 31, 2462–2469 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Moskwa, P. et al. miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol. Cell 41, 210–220 (2011).
  Article CAS PubMed Google Scholar
• Johnson, N. et al. Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nature Med. 17, 875–882 (2011).
  Article CAS PubMed Google Scholar
• Akamatsu, Y. & Jasin, M. Role for the mammalian Swi5−Sfr1 complex in DNA strand break repair through homologous recombination. PLoS Genet. 6, e1001160 (2010).
  Article PubMed PubMed Central Google Scholar
• Mendes-Pereira, A. M. et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol. Med. 1, 315–322 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Brenner, J. C. et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 19, 664–678 (2011). An important paper suggesting that ETS gene fusions may confer PARP-inhibitor sensitivity in prostate cancer.
  Article CAS PubMed PubMed Central Google Scholar
• Edwards, S. L. et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451, 1111–1115 (2008).
  Article ADS CAS PubMed Google Scholar
• Sakai, W. et al. Secondary mutations as a mechanism of cisplatin resistance in _BRCA2_-mutated cancers. Nature 451, 1116–1120 (2008). References 50 and 51 are the first demonstrations of synthetic lethal resistance to PARP inhibitors and platinum drugs in BRCA -mutant cells.
  Article ADS CAS PubMed PubMed Central Google Scholar
• Sakai, W. et al. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in _BRCA2_-mutated ovarian carcinoma. Cancer Res. 69, 6381–6386 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Swisher, E. M. et al. Secondary BRCA1 mutations in _BRCA1_-mutated ovarian carcinomas with platinum resistance. Cancer Res. 68, 2581–2586 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Norquist, B. et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J. Clin. Oncol. 29, 3008–3015 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Rottenberg, S. et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc. Natl Acad. Sci. USA 105, 17079–17084 (2008).
  Article ADS CAS PubMed PubMed Central Google Scholar
• Bouwman, P. et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and _BRCA_- mutated breast cancers. Nature Struct. Mol. Biol. 17, 688–695 (2010).
  Article CAS Google Scholar
• Bunting, S. F. et al. 53BP1 inhibits homologous recombination in _Brca1_-deficient cells by blocking resection of DNA breaks. Cell 141, 243–254 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Jiang, H. et al. The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev. 23, 1895–1909 (2009).
  Article ADS CAS PubMed PubMed Central Google Scholar
• Galanty, Y. et al. Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks. Nature 462, 935–939 (2009).
  Article ADS CAS PubMed PubMed Central Google Scholar
• Soucy, T. A. et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458, 732–736 (2009). This paper provides proof of the concept that targeting additional elements of the DDR and replication machinery, such as neddylation complexes, could provide an alternative approach to cancer therapy.
  Article ADS CAS PubMed Google Scholar
• Lansdorp, P. M. Immortal strands? Give me a break. Cell 129, 1244–1247 (2007).
  Article CAS PubMed Google Scholar
• Diehn, M. et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458, 780–783 (2009).
  Article ADS CAS PubMed PubMed Central Google Scholar
• Zhang, M., Atkinson, R. L. & Rosen, J. M. Selective targeting of radiation-resistant tumor-initiating cells. Proc. Natl Acad. Sci. USA 107, 3522–3527 (2010).
  Article ADS CAS PubMed PubMed Central Google Scholar
• Singh, S. K. et al. Identification of human brain tumour initiating cells. Nature 432, 396–401 (2004).
  Article ADS CAS PubMed Google Scholar
• Bao, S. et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756–760 (2006).
  Article ADS CAS PubMed Google Scholar
• Mantoni, T. S., Lunardi, S., Al-Assar, O., Masamune, A. & Brunner, T. B. Pancreatic stellate cells radioprotect pancreatic cancer cells through beta 1-integrin signaling. Cancer Res. 71, 3453–3458 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Stratton, M. R. Exploring the genomes of cancer cells: progress and promise. Science 331, 1553–1558 (2011).
  Article ADS CAS PubMed Google Scholar
• Stephens, P. J. et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 462, 1005–1010 (2009).
  Article ADS CAS PubMed PubMed Central Google Scholar
• Barber, L. J. et al. Comprehensive genomic analysis of a BRCA2 deficient human pancreatic cancer. PLoS ONE 6, e21639 (2011).
  Article ADS CAS PubMed PubMed Central Google Scholar
• Graeser, M. et al. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin. Cancer Res. 16, 6159–6168 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Polo, S. E. & Jackson, S. P. Dynamics of DNA damage response proteins at DNA breaks: a focus on protein modifications. Genes Dev. 25, 409–433 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Hoeijmakers, J. H. Genome maintenance mechanisms for preventing cancer. Nature 411, 366–374 (2001).
  Article ADS CAS PubMed Google Scholar
• Liu, P. et al. Chromosome catastrophes involve replication mechanisms generating complex genomic rearrangements. Cell 146, 889–903 (2011).
  Article CAS PubMed PubMed Central Google Scholar